Xxxxx Indication. (i) XXXXX shall have the right to continue to develop the Compound for the Xxxxx Indication, as expressly provided in this Section 4.3 and the Transition Plan. XXXXX shall have the right to (x) continue and complete its current Phase II trial for the Xxxxx Indication as in effect on the date hereof under the Transition Plan (the “Existing Phase II Xxxxx Indication Plan”), (y) subject to PFIZER’s approval through the Xxxxx Indication Committee (as defined below), modify and/or expand the trial design for the Existing Phase II Xxxxx Indication Plan (any and all such modifications or expansions, being hereinafter referred to as the “Expanded Phase II Xxxxx Indication Plan”) and implement the Expanded Phase II Xxxxx Indication Plan in accordance with such plan and (z) subject to PFIZER’s approval of the Phase III Xxxxx Indication Plan (as defined below) through the Xxxxx Indication Committee, conduct the Phase III Clinical Study for the Xxxxx Indication in accordance with the Phase III Xxxxx Indication Plan, beginning on the first anniversary of the commencement by PFIZER of the Phase III Clinical Study for NSCLC. By no later than December 31, 2005, XXXXX shall deliver to PFIZER a detailed draft of its Phase III development plan for Compound for the Xxxxx Indication (such plan, as approved and amended from time to time by the Xxxxx Indication Committee, the “Phase III Xxxxx Indication Plan”). All of XXXXX’x development plans and activities (including, without limitation, all protocols, clinical study reports and budgets) for the Compound for the Xxxxx Indication and any material modifications thereto or implementation thereof are subject to approval by PFIZER in its reasonable discretion through the Xxxxx Indication Committee.
